NCT01816971 · REGISTRY CONDITION SEARCH

Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2026-04-21

This phase II trial studies how well carfilzomib, lenalidomide, and dexamethasone before and after stem cell transplant works in treating patients with newly diagnosed multiple myeloma. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from diving. Giving carfilzomib, lenalidomide, and dexamethasone before and after stem cell transplant may kill more cancer cells

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Percentage of Patients Achieving sCR

→

outcome · POSTED

Overall Response Rate, Defined as at Least a Partial Response to Therapy (> PR), at Least Very Good Partial Response (VGPR) and at Least Near Complete Response (nCR) Rate

→

outcome · POSTED

Time to Progression

→

outcome · POSTED

Duration of Response

→

outcome · POSTED

Percentage of Participants With Progression-free Survival (PFS)

→

outcome · POSTED

Percentage of Participants With Overall Survival (OS)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Newly diagnosed, myeloma requiring systemic chemotherapy as per International Myeloma Working Group (IMWG) uniform criteria: * Prior treatment of hypercalcemia or spinal cord compression or active and/or aggressively progressing myeloma with corticosteroids or lenalidomide or bortezomib-based regimens does not disqualify the patient (the treatment dose should not exceed the equivalent of 160 mg of dexamethasone in a 4 week period or not more than 1 cycle) * Bisphosphonates are permitted * Suitable and interested to proceed to ASCT * Measurable disease, prior to initial treatment as indicated by one or more of the following: * Serum monoclonal (M)-protein \>= 0.5 g/dL * Urine M-protein \>= 200 mg/24 hours * If serum protein electrophoresis is felt to be unreliable for routine M-protein measurement, then quantitative immunoglobulin levels are acceptable * Life expectancy of more than 3 months * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Bilirubin \< 1.5 times the upper limit of normal (ULN) * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 2.5 times ULN * Absolute neutrophil count (ANC) \>= 1.0 x 10\^9/L * Hemoglobin \>= 8 g/dL * Platelet count \>= 75 x 10\^9/L; subjects may receive red blood cell (RBC) transfusions or platelet transfusions, if clinically indicated in accordance with institutional guidelines; however, screening platelet count should be independent of platelet transfusions for at least 2 weeks * Calculated or measured creatinine clearance of \>= 50 mL/minute, calculated using the formula of Cockcroft and Gault * Written informed consent in accordance with federal, local, and institutional guidelines * Females of childbearing potential (FCBP) (defined as sexually mature females who: have not undergone a hysterectomy or bilateral oophorectomy; or have not been naturally postmenopausal for at least 24 consecutive months \[ie, has had menses at any time in the preceding 24 consecutive months\]) must agree to ongoing pregnancy testing * FCBP must have 2 negative pregnancy tests (sensitivity of at least 50 mIU/mL) prior to initiating lenalidomide; the first pregnancy test must be performed within 10-14 days before day 1 cycle 1 and the second pregnancy test must be performed within 24 hours of day 1 cycle 1; the subject may not receive lenalidomide until the treating investigator has verified that the results of these pregnancy tests are negative, and must agree to ongoing pregnancy tests as outlined in the protocol * FCBP must agree to use 2 reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse during the following time periods related to this study: * For at least 28 days before starting lenalidomide * While participating in the study; and * For at least 28 days after discontinuation from the study; the 2 methods of reliable contraception must include a highly effective method (ie, intrauterine device (IUD), hormonal \[birth control pills, injections, or implants\], tubal ligation, partner's vasectomy) and an additional effective (barrier) method (ie, latex condom, diaphragm, cervical cap); FCBP must be referred to a qualified provider of contraceptive methods if needed * Male subjects must agree to use a latex condom during sexual contact with females of childbearing potential while participating in the study and for at least 28 days following discontinuation from the study even if he has undergone a successful vasectomy * Male subjects must agree to inform his physician if he has had unprotected sexual contact with a female who can become pregnant or if he thinks for any reason that his sexual partner may be pregnant * Male subjects must agree not to donate semen or sperm while taking lenalidomide * All study participants must be registered into the mandatory Rev Assist program and be willing and able to comply with the requirements of Rev Assist * The ability to take aspirin or other appropriate venous thromboembolism (VTE) prophylaxis * Subjects must agree to adhere to all study requirements, including birth control measures and pregnancy testing, visit schedule, outpatient treatment, required concomitant medications, and laboratory monitoring Exclusion Criteria: * Non-secretory or hyposecretory multiple myeloma, prior to initial treatment defined as \< 0.5 g/dL M-protein in serum, \< 200 mg/24 hr urine M-protein, or disease only measured by serum free light chain * POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) * Waldenstrom's macroglobulinemia or immunoglobin (Ig)M myeloma * Radiotherapy to multiple sites or immunotherapy within 4 weeks before start of protocol treatment (localized radiotherapy to a single site at least 1 week before start is permissible) * Participation in an investigational therapeutic study within 3 weeks or within 5 drug half-lives (t1/2) prior to first dose, whichever time is greater * Pregnant or lactating females * History of allergy to mannitol * Major surgery within 3 weeks prior to first dose * Myocardial infarction within 6 months prior to enrollment, New York Heart Association (NYHA) class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities * Uncontrolled hypertension or diabetes * Acute active infection requiring systemic antibiotics, antivirals, or antifungals within two weeks prior to first dose * Known or suspected human immunodeficiency virus (HIV) infection, known HIV seropositivity * Active hepatitis A, B, or C infection * Non-hematologic malignancy within the past 3 years except adequately treated basal cell, squamous cell skin cancer, thyroid cancer, carcinoma in situ of the cervix, or prostate cancer \< Gleason grade 6 with stable prostate specific antigen levels or cancer considered cured by surgical resection alone * Any clinically significant medical disease or condition that, in the investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent * Significant neuropathy (grades 3-4, or grade 2 with pain) at the time of the first dose and/or within 14 days before enrollment * Contraindication to any of the required concomitant drugs, including proton-pump inhibitor (eg, lansoprazole), enteric-coated aspirin, allopurinol or if a history of prior thrombotic disease, warfarin or low molecular weight heparin * Subjects in whom the required program of PO and IV fluid hydration is contraindicated, eg, due to pre-existing pulmonary, cardiac, or renal impairment * Subjects with known or suspected amyloidosis of any organ * Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis * No coverage or not-acceptable by patient co-pay for lenalidomide
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
INDUCTION THERAPY: Patients receive dexamethasone IV or PO QD on days 1, 8, 15 and 22; carfilzomib IV over 10-30 minutes on days 1, 2, 8, 9, 15, and 16; and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.. TRANSPLANT: Patients undergo autologous stem cell transplant. CONSOLIDATION THERAPY: Patients receive dexamethasone, carfilzomib, and lenalidomide as in induction. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. MAINTENANCE THERAPY: Patients receive dexamethasone and lenalidomide as in induction therapy and carfilzomib IV over 30 minutes on days 1, 2, 15, and 16. Treatment repeats every 28 days for 10 courses in the absence of disease progression or unacceptable toxicity.
intervention Names
Drug: dexamethasone
Drug: carfilzomib
Drug: lenalidomide
Procedure: autologous hematopoietic stem cell transplantation
Other: laboratory biomarker analysis
label
Treatment (dexamethasone, carfilzomib, lenalidomide)
type
EXPERIMENTAL

interventions

arm Group Labels
Treatment (dexamethasone, carfilzomib, lenalidomide)
description
Given IV or PO
name
dexamethasone
other Names
Aeroseb-Dex
Decaderm
Decadron
DM
DXM
type
DRUG
arm Group Labels
Treatment (dexamethasone, carfilzomib, lenalidomide)
description
Given IV
name
carfilzomib
other Names
Kyprolis
PR-171
type
DRUG
arm Group Labels
Treatment (dexamethasone, carfilzomib, lenalidomide)
description
Given PO
name
lenalidomide
other Names
CC-5013
IMiD-1
Revlimid
type
DRUG
arm Group Labels
Treatment (dexamethasone, carfilzomib, lenalidomide)
description
Undergo autologous hematopoietic stem cell transplant
name
autologous hematopoietic stem cell transplantation
type
PROCEDURE
arm Group Labels
Treatment (dexamethasone, carfilzomib, lenalidomide)
description
Correlative studies
name
laboratory biomarker analysis
type
OTHER

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 76
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
The percentage of stringent complete response (CR) (sCR) will be reported along with 95% confidence intervals, adjusted for the two-stage nature of the trial design.
measure
Percentage of Patients Achieving sCR
time Frame
Day 224

secondary Outcomes

description
Reported along with its exact 95% binomial confidence interval.
measure
Overall Response Rate, Defined as at Least a Partial Response to Therapy (> PR), at Least Very Good Partial Response (VGPR) and at Least Near Complete Response (nCR) Rate
time Frame
Up to 5 years
description
Estimated using the product-limit method of Kaplan and Meier.
measure
Time to Progression
time Frame
Up to 5 years
description
Reported along with its exact 95% binomial confidence interval. Estimated using the product-limit method of Kaplan and Meier.
measure
Duration of Response
time Frame
Up to 5 years
description
Progression-free Survival rate was estimated at months 12, 24, 36, 48, and 60, by the product-limit method of Kaplan and Meier.
measure
Percentage of Participants With Progression-free Survival (PFS)
time Frame
Up to 5 years
description
Overall survival rate was estimated at months 12, 24, 36, 48, and 60, by the product-limit method of Kaplan and Meier.
measure
Percentage of Participants With Overall Survival (OS)
time Frame
Up to 5 years

Full study description

brief Summary: This phase II trial studies how well carfilzomib, lenalidomide, and dexamethasone before and after stem cell transplant works in treating patients with newly diagnosed multiple myeloma. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from diving. Giving carfilzomib, lenalidomide, and dexamethasone before and after stem cell transplant may kill more cancer cells
detailed Description: PRIMARY OBJECTIVES: I. To determine the rate of stringent complete response (CR) (sCR) after 8 cycles of CRd (4 cycles of induction + autologous stem cell transplant \[ASCT\] + 4 cycles of carfilzomib, lenalidomide, and low dose dexamethasone \[CRd\] consolidation). SECONDARY OBJECTIVES: I. Overall response rate defined as partial response or better (\>= partial response \[PR\]) including the rate of very good partial response (VGPR) or better (\>= VGPR) and near complete response or better (sCR/CR/nCR) across entire treatment in high risk and low risk patients. II. Duration of response (DOR), progression free survival (PFS), time to progression (TTP), and overall survival (OS). TERTIARY OBJECTIVES: I. Determination of the rate of minimal residual disease in patients who achieved CR. II. Prospective evaluation of candidate markers of response to CRd established in the completed CRd trial. III. Evaluation of markers of response and duration of response to treatment strategy using CRd with or without transplant. OUTLINE: INDUCTION THERAPY: Patients receive dexamethasone intravenously (IV) or orally (PO) once daily (QD) on days 1, 8, 15 and 22; carfilzomib IV over 10-30 minutes on days 1, 2, 8, 9, 15, and 16; and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.. TRANSPLANT: Patients undergo autologous stem cell transplant. CONSOLIDATION THERAPY: Patients receive dexamethasone, carfilzomib, and lenalidomide as in induction. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. MAINTENANCE THERAPY: Patients receive dexamethasone and lenalidomide as in induction therapy and carfilzomib IV over 30 minutes on days 1, 2, 15, and 16. Treatment repeats every 28 days for 10 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 2 years.

Source references

references

citation
Landgren O, Kazandjian D, Roussel M, Jasielec J, Dytfeld D, Anderson A, Kervin TA, Iskander K, McFadden I, Jakubowiak AJ. Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma: pooled analysis of four single-arm studies. Leuk Lymphoma. 2022 Oct;63(10):2413-2421. doi: 10.1080/10428194.2022.2068001. Epub 2022 May 12.
pmid
35549810
type
DERIVED
citation
Jasielec JK, Kubicki T, Raje N, Vij R, Reece D, Berdeja J, Derman BA, Rosenbaum CA, Richardson P, Gurbuxani S, Major S, Wolfe B, Stefka AT, Stephens L, Tinari KM, Hycner T, Rojek AE, Dytfeld D, Griffith KA, Zimmerman TM, Jakubowiak AJ. Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. Blood. 2020 Nov 26;136(22):2513-2523. doi: 10.1182/blood.2020007522.
pmid
32735641
type
DERIVED

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-061b41156cc221f5969b
requested nct id
NCT01816971
primary nct id
NCT01816971
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
5c5168794e05e8c54cd88c75e1d13629b22d10efaff9babf8a225f94694ccbe6
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-061b41156cc221f5969b
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01816971
occurrences
context exact
NCT01816971
end
11
exact text
NCT01816971
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/406/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
a4d8c2358ef6edcfad16ca1767e62e013ddfeb8fb859471165ab47826eb3183c
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice